Should I Buy IMRX? IMRX 2026 Analysis

Should You Buy Immuneering Corp (IMRX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

5.250

1 Day change

4.37%

52 Week Range

10.080

Analysis Updated At

2026/02/20

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Immuneering Corp (IMRX) is a good buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The technical indicators are bullish, insider buying is strong, and the options data reflects a positive sentiment. While the financials are weak, the company's niche in pancreatic cancer treatment and encouraging analyst ratings suggest long-term potential.

Technical Analysis

The MACD is positive and expanding (0.0837), RSI is neutral at 66.036, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading above key pivot levels, with resistance at 5.209 and 5.39, indicating a bullish trend.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Insider buying increased by 266.10% over the last month.
Encouraging analyst sentiment with an Outperform rating based on Phase 2a trial data for pancreatic cancer treatment.
Bullish technical indicators and positive stock trend probabilities (70% chance to rise 3.95% in the next week).

Neutral/Negative Catalysts

Weak financial performance with no revenue and a net income loss of -$14,964,875 in Q3
EPS dropped by -22.45% YoY.

Financial Performance

In Q3 2025, the company reported no revenue growth (0% YoY), net income loss of -$14,964,875 (up 2.52% YoY), and a decline in EPS to -0.38 (-22.45% YoY).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst Leerink has an Outperform rating on IMRX, citing impressive 64% landmark overall survival (OS) data from Phase 2a trials in pancreatic cancer. However, median progression-free survival (PFS) is 8.5 months, similar to competitors, but IMRX may have a safety advantage for frailer patients.

4 Analyst Rating

Wall Street analysts forecast IMRX stock price to rise

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 5.030

Low

Averages

14.5

High

Current: 5.030

Low

Averages

14.5

High

Leerink

Outperform

maintain

$NULL

AI Analysis

2026-01-08

Reason

Leerink

Price Target

$NULL

AI Analysis

2026-01-08

maintain

Outperform

Reason

After Immuneering (IMRX) announced updated overall survival and safety data from its ongoing Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients, Leerink says the updated 12 month data highlights "impressive" 64% landmark OS, which the analyst calls "encouraging." The median progression free survival deteriorated to 8.5 months, which the analyst notes is similar to the 8.5 months shown by Revolution Medicines' (RVMD) daraxonrasib in second-line PDAC, but adds that Immuneering may have a safety advantage that "could facilitate a niche in frailer patients." Leerink has a Outperform rating on Immuneering shares, which are down $3.37, or 40%, to $4.96 in afternoon trading.

Leerink

Outperform

initiated

$15

2025-10-31

Reason

Leerink

Price Target

$15

2025-10-31

initiated

Outperform

Reason

Leerink initiated coverage of Immuneering with an Outperform rating and $15 price target. The firm notes lead asset atebimetinib is an allosteric MEK inhibitor that has shown compelling Phase 2 activity in combination with chemotherapy in first-line pancreatic ductal adenocarcinoma, a tumor type in which over 90% of patients are driven by aberrant, constitutive MAPK signaling. Leerink thinks DCI, which departs from conventional, continuous kinase inhibition and uses high dose, pulsatile blockade, introduces mechanistic risk. However, it sees significant upside if efficacy and tolerability are confirmed in the pivotal trial by allowing a more tolerable approach to MEK inhibition. The firm views atebi as a blockbuster+ agent in PDAC with $2.4B peak revenues, representing $14/share in its model.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IMRX

Unlock Now

IMRX Should I Buy

IMRX Should I Buy

Should You Buy Immuneering Corp (IMRX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch